Related Experiment Video
Updated: Aug 17, 2025
09:43
Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging
Published on: January 10, 2025
1.3K
Salusins: advance in cardiovascular disease research
Ming-Xin Chen1,2, Bo-Yan Deng1,2, Shu-Ting Liu1,2
1Institute of Pharmacy and Pharmacology, University of South China, Hengyang, China.
The Journal of Pharmacy and Pharmacology
|December 12, 2022
Summary
Salusins, bioactive peptides, regulate lipid metabolism and vascular proliferation. Further research is needed to determine their exact cardiovascular effects and potential as disease biomarkers.
Area of Science:
- Biochemistry
- Physiology
- Cardiovascular Research
Background:
- Salusins (salusin-α and salusin-β) are bioactive peptides discovered in 2003 with known hemodynamic and mitotic activities.
- These peptides are primarily found in plasma, urine, endocrine glands, and kidneys, influencing lipid metabolism, inflammation, and vascular proliferation.
Approach:
- This review synthesizes current research on salusins' physiological properties.
- It explores their potential mechanisms of action in cardiovascular diseases like atherosclerosis, hypertension, heart failure, myocardial infarction, and myocarditis.
- The review also examines salusins as potential biomarkers for cardiovascular disease detection.
Key Points:
- Salusins exhibit diverse physiological roles, including regulation of lipid metabolism and vascular proliferation.
- The precise mechanisms underlying salusins' cardiovascular effects require further elucidation.
- Salusins show promise as potential diagnostic and prognostic biomarkers for various cardiovascular conditions.
Conclusions:
- Understanding salusin mechanisms is crucial for developing novel therapeutic strategies.
- Salusins may offer new avenues for the diagnosis and prevention of clinical cardiovascular diseases.
- This review highlights the need for continued investigation into salusin's role in cardiovascular health.
More Related Videos
08:08Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
Published on: June 10, 2015
11.4K
04:52Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique
Published on: September 13, 2022
2.4K
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
46
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
46
01:29Heart Failure II: Pathophysiology
23
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
482
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
482
01:26Atherosclerosis III: Management
19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
36
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
36
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19